Sonnet Biotherapeutics Holdings, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Sonnet BioTherapeutics reported increased net losses for the nine months ended June 30, 2025, while advancing its clinical pipeline and announcing a definitive merger agreement with Hyperliquid Strategies Inc.
Sonnet BioTherapeutics reports its financial results for the quarter ended March 31, 2025, highlighting clinical trial advancements and pipeline development amid ongoing financial challenges.
Sonnet BioTherapeutics reports its financial results for the quarter ended December 31, 2024, and provides an update on its clinical programs and recent developments.
10-Q: Sonnet BioTherapeutics Reports Q3 2024 Results, Cites Ongoing Clinical Progress and Cost Management
Sonnet BioTherapeutics reported its Q3 2024 financial results, highlighting clinical trial advancements and ongoing cost-cutting measures.
Sonnet BioTherapeutics reported its Q2 2024 financial results, highlighted by a net income of $365,425 and the establishment of a $25 million committed equity facility.
Sonnet BioTherapeutics reported a net loss of $1.2 million for the quarter ended December 31, 2023, while implementing cost-cutting measures and advancing clinical programs.